1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

5/994 pts enrolled: 496 pembro vs 498 placebo. Median time from rand. to data-cutoff (Sep 15 2023): 57.2 months (range 47.9-74.5, close to 5 years)

Baseline characteristics:

6/ A significant and clinically meaningful OS benefit was observed with adjuvant pembro vs placebo:

HR 0.62; 95% CI 0.44-0.87; P = 0.005

At 48 months: 91% of pts receiving pembro were still alive vs 86% with placebo (5% absolute benefit)

7/ OS benefit was consistent across subgroups

Of note, the OS benefit was consistent in the M0 intermediate-high risk pts (HR 0.59; 95% CI 0.40 to 0.87) while sample sizes & number of deaths were small in the M0 high risk pts and M1 NED, leading to wider CIs.

8/ Updated DFS results aligned with previous analyses:

DFS benefit for pembro: HR 0.72 (95% CI 0.59 to 0.87), generally consistent across subgroups

9/The rates of pts receiving subsequent therapies, consisting in radiation, surgery or systemic treatment, are displayed below.

10/ Safety findings were consistent with prior analyses (as all patients had d/c therapy since Dec 2020):

Congratulations to Dr. Bernard Escudier on receiving the Nicholas J. Vogelzang Humanitarian Award at the 2024 International Kidney Cancer Symposium. His dedication to medical oncology and humanitarian efforts,patient advocacy are truly inspirational and deserving of this…

Vivek Subbiah, MD Sumanta K. Pal, MD, FASCO Anthony Scott Fernando Sabino M Monteiro Juan Pablo Sade Andrey Soares André P. Fay Ray Manneh Kopp CLOC: Curso Latinoamericano de Oncología Clínica Asociación Argentina de Oncología Clínica (AAOC) Mauricio Fernandez L Martín Angel Sabine D. Brookman-May Petros Grivas Uromigos Tom Powles Dr. Tomás Soulé Advanced Prostate Cancer Consensus Conference 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Simon C Cristiane D Bergerot GUARD Consortium Federico Cayol Gil Morgan, MD Enrique Grande Ishwaria Subbiah, MD MS FASCO ESMO - Eur. Oncology Laura Caba Fundación SOLTI Kristof V Maite Bourlon Michael Hofman Declan Murphy ProsTIC ylt David Lorente UroTeragLATAM Rodrigo Coutinho Mariano Rodrigo Sanchez Roger Roger Li Darren Poon ANZUP Andrea Apolo, M.D.

📢 Our latest clinical study ‘’Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT trial)’’ is now out!

ClinicalTrialGov n. NCT06302569

#CancerResearch #oncology
AIOM ANTURE - Associazione Nazionale Tumore del Rene Meet-URO The Renal Medullary Carcinoma Research Foundation Tumori Journal IKCC Kidney Cancer

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

🚀Nuevo Ensayo clínico en melanoma!!🔬 En el #Hospital12deOctubre se acaba de abrir un ensayo en primera línea con TILs para tratar el melanoma. 💪 ¡Una nueva prometedora opción! #InvestigaciónMédica #Melanoma #Hospital12deOctubre clinicaltrials.gov/study/NCT05727…

📍Una cita imprescindible para ponerte al día!! Vídeos cortos con novedades terapéuticas en los tumores GU con Enrique Grande Elena Sevillano M.D. PhD Javier Molina Cerrillo Álvaro Pinto MJosé Juan y mucho mas!! 👇👇

Thank you UMass Cancer Center and KMittaloncMD for the kind invitation for @UMass Grand Rounds!

Dana-Farber Lank Center for Genitourinary Oncology OncoAlert

The 3rd transatlantic exchanges between Dana-Farber and Gustave Roussy happening April 12 in City of Boston —come join us in person or virtually ! Topic: liquid biopsies in Cancer! Laurie Glimcher MD Fabrice Barlesi FabriceAndre #Fizazi OncoAlert logy

na.eventscloud.com/website/68476/

Debates en Oncología - Cáncer genitourinario, post ASCO GU 2024.
Os presentamos la 5ª edición (¡que no es poco!) 😯🔝
Un año más, con los coordinadores científicos, el Dr. Javier Puente y el Dr. Guillermo de Velasco 🙌🏼

No te lo pierdas, ¡Dale clic! ⬇️⬇️⬇️
transworldeditors.com/debates-en-onc…

Horizontal thinking saved my life…

I didn't have a billion dollars or ten years to develop a new drug from scratch. My survival hinged on one critical strategy: identifying and repurposing an existing drug made for another disease to treat my own.

This approach isn't just a…

Belzutifan, a HIF-2α inhibitor, has been approved by the U.S. FDA for the treatment of patients with #kidneycancer previously treated with immune checkpoint inhibitors and anti-angiogenic therapies.

This study was led by a study led by Toni Choueiri, MD.

ms.spr.ly/6019iwggf

📻 Stay tuned!
🎤 We will be presenting our #BladderGATE trial data at #EAU24 in Paris
🔴 BCG-naïve #NMIBC patients treated with BCG + atezolizumab
Daniel Castellano European Association of Urology (EAU) GUO-AEU Department of Urology, Hospital 12 De Octubre World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network Guillermo de Velasco Marta Dueñas blatam uro UroSoMe soc.urológica.madrid

Thanks to colleagues around the globe for your support of the ASCO elections!

Ready to get to work to deliver on ASCO goals relating to access, knowledge and the profession!

Let us do this together !

—Toni